Compile Data Set for Download or QSAR
Report error Found 53 Enz. Inhib. hit(s) with all data for entry = 50001927
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450569(CHEMBL4176676)
Affinity DataEC50:  310nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450522(CHEMBL4163788)
Affinity DataEC50:  150nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450558(CHEMBL4175244)
Affinity DataEC50: >1.00E+5nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450559(CHEMBL4168046)
Affinity DataEC50:  2.30E+3nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450560(CHEMBL4160124)
Affinity DataEC50: >1.00E+5nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450561(CHEMBL4163433)
Affinity DataEC50:  1.50E+4nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450562(CHEMBL4162598)
Affinity DataEC50:  200nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450563(CHEMBL4170528)
Affinity DataEC50:  6.60E+3nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450564(CHEMBL4173966)
Affinity DataEC50: >3.20E+3nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450565(CHEMBL4174354)
Affinity DataEC50:  1.10E+3nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450566(CHEMBL4159213)
Affinity DataEC50:  73nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450567(CHEMBL4167124)
Affinity DataEC50:  1.50E+3nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450568(CHEMBL4176234)
Affinity DataEC50:  1.10E+3nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450557(CHEMBL4166939)
Affinity DataEC50:  2.20E+4nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450570(CHEMBL4168819)
Affinity DataEC50:  460nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450571(CHEMBL4173309)
Affinity DataEC50:  100nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450572(CHEMBL4164975)
Affinity DataEC50:  1nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450549(CHEMBL4174690)
Affinity DataEC50:  4nMAssay Description:Inhibition of RSV A2 fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK8 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450549(CHEMBL4174690)
Affinity DataEC50:  2nMAssay Description:Inhibition of RSV B fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK8 a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450573(CHEMBL4164613)
Affinity DataEC50:  7.80E+3nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450574(CHEMBL4176303)
Affinity DataEC50:  2.30E+3nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450575(CHEMBL4166043)
Affinity DataEC50:  120nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450576(CHEMBL4163677)
Affinity DataEC50:  320nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450577(CHEMBL4177084)
Affinity DataEC50:  230nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450578(CHEMBL4165392)
Affinity DataEC50:  4nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450579(JNJ 2408068 | JNJ-240806 | JNJ-2408068 | R-170591)
Affinity DataEC50:  0.160nMAssay Description:Inhibition of RSV Long fusion protein assessed as decrease in virus induced syncytium formation in infected human HeLa/M cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450543(CHEMBL4162290)
Affinity DataEC50:  280nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450523(CHEMBL4174923)
Affinity DataEC50:  39nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450524(CHEMBL4160231)
Affinity DataEC50:  41nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450525(CHEMBL4175600)
Affinity DataEC50:  7nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450526(CHEMBL4162982)
Affinity DataEC50:  27nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450527(CHEMBL4167240)
Affinity DataEC50:  14nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450534(CHEMBL4176580)
Affinity DataEC50:  37nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450538(CHEMBL4170626)
Affinity DataEC50:  10nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450539(CHEMBL4168325)
Affinity DataEC50:  14nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450540(CHEMBL4167426)
Affinity DataEC50:  25nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450541(CHEMBL4161097)
Affinity DataEC50:  12nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450542(CHEMBL4170204)
Affinity DataEC50:  540nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450556(CHEMBL4174832)
Affinity DataEC50:  220nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450544(CHEMBL4167039)
Affinity DataEC50:  71nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450545(CHEMBL4163590)
Affinity DataEC50:  26nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450546(CHEMBL4159997)
Affinity DataEC50:  3.10E+3nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450547(CHEMBL4176594)
Affinity DataEC50:  5nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450548(CHEMBL4162082)
Affinity DataEC50:  31nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450549(CHEMBL4174690)
Affinity DataEC50:  2nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450550(CHEMBL4165626)
Affinity DataEC50:  5.60E+3nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450551(CHEMBL4169881)
Affinity DataEC50:  11nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450552(CHEMBL4161955)
Affinity DataEC50:  230nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450553(CHEMBL4166459)
Affinity DataEC50:  62nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50450554(CHEMBL4171388)
Affinity DataEC50:  220nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
Displayed 1 to 50 (of 53 total ) | Next | Last >>
Jump to: